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Reasons for project closures from AstraZeneca 

























































































































































































































































































































































Fee for Services 
Private Donors 
Charities or Nonprofits 
For profit commercial organizations 
Disease Advocacy / Foundations 
IP Revenue Generated by ADDC 
University or Academic Unit 










ADDCs that support each phase of the drug discovery process 
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Therapeutic areas supported 
Percent of ADDC Respondents (N=42) 
Therapeutic approaches supported 































Creation of IP 
Compounds reach Clinical Trials 
Education 
Publication 
Important priorities in ADDC mission 




















































































































































































Familiar, but has not attended events 
Engaged via event attendance 
Active participant 
Familiarity with CDNM by UofM PIs 
Percent of survey respondents (n=115) 
Translation funding recommendations 






Interdisciplinary Center (CDNM, MICHR etc) 
Core Lab Facilities 
Own Department 
Office of Technology Transfer 
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No. Contact Name Affiliation Title / Department Category 
Connection 
Made Via 
1 Jim Shayman 
University of 
Michigan 
Nephrologist and Inventor 
of Cerdelga Academia CDNM / LSI 
2 Max Wicha University of Michigan 
Director, Comprehensive 
Cancer Center Academia CDNM / LSI 
3 Aaron Westfall 
University of 
Michigan Business Development, LSI Academia CDNM / LSI 
4 Laura Williams 
University of 
Michigan Business Development, LSI Academia CDNM / LSI 
5 Ian Dempsky University of Michigan 
Marketing/Communications, 
LSI Academia CDNM / LSI 
6 Robin Rasor University of Michigan 
Managing Director of 
Licensing, Office of Tech 
Transfer 
Academia 
CDNM / LSI 
7 Jack Minor University of Michigan 
Director of Venture Center, 
Office of Tech Transfer Academia CDNM / LSI 
8 Ann Schork University of Michigan Managing Director, LSI Academia CDNM / LSI 
9 Eric Fearon University of Michigan 
Chief of the Division of 
Molecular Medicine & 
Genetics 
Academia 
CDNM / LSI 
10 Ed Pagani University of Michigan 
Senior Licensing Specialist, 
Office of Tech Transfer Academia CDNM / LSI 
11 Connie Chang 
University of 
Michigan 
Managing Director, Fast 
Forward Medical Innovation Academia 
CDNM / LSI 
12 Tom Shanley University of Michigan 
Director, Michigan Institute 
for Clinical and Health 
Research 
Academia 
CDNM / LSI 
13 Shaomeng Wang 
University of 
Michigan 
Research Scientist and 
Director, Cancer Drug 
Discovery Program 
Academia 
CDNM / LSI 
14 John Tesmer University of Michigan Research Scientist, LSI Academia CDNM / LSI 
15 James Dalton 
University of 
Michigan Dean, College of Pharmacy Academia CDNM / LSI 
16 Lori Isom University of Michigan 
Interim Chair, College of 
Pharmacology Academia CDNM / LSI 
17 Jeanne Stuckey 
University of 
Michigan Head of SAR Core Academia CDNM / LSI 




Coordinator and Finance 
Manager, LSI 
Academia 





19 Martha Larsen 
University of 
Michigan Director of HTS Core, LSI Academia CDNM / LSI 
20 Scott Larsen University of Michigan 
Director of Vahlteich 
Medicinal Chemistry Core, 
College of Pharmacy 
Academia 
CDNM / LSI 
21 Duxin Sun University of Michigan 
Director of PK Core, 
College of Pharmacy Academia CDNM / LSI 
22 Rajesh Ranganathan NIH (NINDS) Director of NINDS, NIH Academia CDNM / LSI 
23 Stephen Frye University of North Carolina 
Director, Center for 
Integrative Chemical 
Biology and Drug Discovery 
Academia 
MAP Team 
24 David Walt Tufts University 
Director, Tufts Institute for 
Innovation Academia CDNM / LSI 





Chief Scientific Officer, 









Senior Associate Director Academia 
MAP Team 
27 Issi Rozen Broad Institute Senior Director, Strategic Alliances Academia MAP Team 








CDNM / LSI 
29 Mike Walters University of Minnesota 
Director, Lead and Probe 
Discovery Core, Institute for 








Associate Director Academia 
MAP Team 






32 Donna See Allied Minds Vice President, University Relations VC CDNM / LSI 
33 Doug Cole Flagship Ventures Managing Partner VC CDNM / LSI 
34 Michael Gladstone Atlas Ventures Principal VC MAP Team 
35 Larry Lasky The Column Group Partner VC CDNM / LSI 





37 Kristina Burrow 
ARCH Venture 
Partners Managing Director VC CDNM / LSI 
38 Anthony Philippakis 
Google 
Ventures Partner VC MAP Team 
39 Several Contacts Apjohn Group   Industry CDNM / LSI 
40 John Freshley 
ONL 
Therapeutics President and CEO Industry MAP Team 
41 Sridar Natesan Sanofi 
Head of R&D, External & 
Academic Alliances Industry CDNM / LSI 
42 Adam Keeney Sanofi 
Head of R&D, External & 
Academic Alliances Industry MAP Team 
43 Morrie Birnbaum Pfizer CSO, Cambridge CTI Industry CDNM / LSI 
44 Kiran Reddy Biogen Senior Director, Corporate Strategy Industry CDNM / LSI 
45 Scott Lewis Biogen Senior Director, Corporate Strategy Industry MAP Team 
46 Rose Loughlin Biogen 
Senior Manager, Business 
Development Industry MAP Team 
47 Ann Schlesinger Novartis 
Industry-Academia Liaison, 
Novartis Institutes for 
Biomedical Research 
Industry 
CDNM / LSI 
48 Ron Newbold Pfizer 
Head, Strategic Research 




49 Maude Tessier Merck 
Director, Business 




50 Gus Gustavson 
J&J Innovation 
Center 
Vice President, CVM 





















































































































































































































































































Core Services Integration: The	center	collaborates	with	PIs	after	evaluating	their	proposals	
based	on	description	of	the	target	and	assay	development,	funding	status	and	outlook,	and	
alignment	with	center’s	project	portfolio.	Once	a	proposal	has	been	accepted,	a	formal	
project	plan	is	created,	outlining	the	extent	of	the	center’s	capabilities	to	be	utilized	over	
the	course	of	the	project60. The	center’s	director	and	core	lab	directors	then	work	with	the	
PIs	as	collaborators	on	projects,	often	jointly	submitting	grants	to	move	projects	forward.	
There	is	a	scientific	advisory	board	that	helps	assess	the	center’s	portfolio	and	project	
process,	but	no	specific	project	management	is	in	place	for	each	project.	The	combination	
of	the	center’s	capabilities	and	operations	has	resulted	in	$22	million	follow-on	grant	
funding	over	the	past	8	years,	with	the	center	collaborating	on	5-6	projects	with	PIs	every	
year. 
		
Key	Takeaway:	The	key	selling	point	of	the	center	is	its’	core	capabilities	and	focus	on	
project	collaboration	(without	a	fee-for-service	component).	Although	it	does	not	operating	
as	a	seed	funding	program	or	provide	formal	educational	support,	the	relationship	that	the	
core	labs	have	with	PIs	on	project	progress,	publishing,	and	grants	has	resulted	in	the	
center’s	success	in	receiving	continued	grant	funding. 	
Stanford	Chemistry,	Engineering	&	Medicine	for	Human	Health	(ChEM-H)	
Background:	Established	in	2014	as	a	nexus	for	interdisciplinary	research,	spanning	
biology,	chemistry,	medicine,	and	engineering	for	promotion	of	human	health,	the	center,	
funded	by	the	university,	currently	provides	$50,000	in	seed	funding	to	projects	that	
require	interdisciplinary	PI	involvement.	ChEM-H	has	also	established	“knowledge	centers”	
for	medicinal	chemistry	and	structural	biology	(still	in	pilot	phase)	which	have	an	expert	in	
each	core	function	who	are	set	up	to	be	consultants	and	collaborators.	The	center	pays	for	
20%	of	the	salary	for	these	experts	to	act	in	a	consulting	capacity	for	ChEM-H	projects,	
which	is	separate	from	the	direct	work	that	the	experts	do	beyond	on	a	project	itself.	
		
Education Component: A	key	aspect	of	ChEM-H	is	its	emphasis	on	education	and	
collaboration.	ChEM-H	faculty	fellows	mentor	postdoctoral	students	and	spearhead	events,	
while	students	have	created	a	ChEM-H	Postdoctoral	Society,	where	postdocs	create	a	
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community,	interact	with	ChEM-H	leadership,	and	gain	advice	from	faculty.	Novartis	and	
ChEM-H	also	collaborate	on	an	educational	program	meant	to	bridge	understanding	
between	industry	and	academia61.	Components	of	the	collaboration	include	a	case-based	
simulation	course,	teaching	PIs	from	different	disciplines	to	understand	each	other	and	
drug	discovery,	informal	networking	sessions,	a	seminar	series	involving	academics	and	
industry,	and	an	agreement	in	which	Stanford	chemistry	PhD	candidates	are	eligible	for	an	
internship	before	starting	their	studies. 
		
Key	Takeaway:	ChEM-H	emphasizes	creating	a	collaborative	community	within	the	
university,	with	education	a	critical	component.	Bridging	gaps	in	translational	research	
knowledge,	between	disciplines,	and	gaps	between	investigators	drive	the	seed	funding	
requirements,	collaboration	with	Novartis,	and	faculty	mentoring.	ChEM-H	is	another	
example	that	highlights	not	only	the	need,	but	also	the	interest	in	learning,	training,	and	
relationship	building	within	an	ADDC	community.	
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